Home > Back to Publisher > Report Information

The Global Image Dermatology Drug Market, 2005-2012: High-Growth Opportunities in Aesthetic Medicine

Spectra Intelligence
November 1, 2005
153 Pages - SKU: SPIN1666305

Abstract Table of Contents Search inside this report Related Reports

Countries covered: Global

Examines the global market for aesthetic dermatologicals and specialty physician-dispensed drugs to treat conditions associated with deficits in physical image and form. Drugs such as botulinum toxins, retinoids, acid peels, 5-alpha reductase and lipase inhibitors associated with cutaneous ageing, photodamage, pigmentation defects, alopecia, and the lipodermal disorders of obesity and gynoid lipodystrophy are critically discussed to provide a detailed analysis of the high-growth market sector estimated at US$1.8 billion in 2005 and forecast to increase by 114% to US$3.9 billion by 2012. The report includes insights for product extension and optimization, sales forecasts to 2012, and impact of late-stage pipeline drugs on the market. Therapy area forecasting and illustrative market data and analysis is also presented to gain insight into top-performing products and therapy areas.

REPORT HIGHLIGHTS AND KEY FINDINGS

Dermatological drugs indicated for image dermatology account for a market valued at US$1.8 billion, which is predicted to increase 114% CAGR to 2012
Critical analysis of alopecia, cutaneous ageing, photodamage, pigmentation deficits, obesity, cellulite and other lipodermal conditions
Comprehensive review of epidemiological, aetiological, and therapeutic data for 5 key therapy areas
Analysis of over 20 marketed products and inclusion of 45 R&D candidates identified in preclinical to clinical stages of development
Sales estimates (US$) to 2012 for critical therapy areas
Strategic insights for life-cycle optimization and product development
Evaluation of leading products and major competitors
Emerging markets identified and sector analysis
Trend analysis of industry events and activities over past 2 years
Detailed R&D themes and clusters by therapy area
Data generation on sector and market values between 2004 and 2012 and therapy forecasts by 2020 (US$)
High revenue-yielding prospects identified with projected sales estimations
R&D pipeline positioning for all therapy areas
Market insights for product development and drug promotion

WHAT CAN I LEARN FROM THIS REPORT?

What the main therapy areas are within the image dermatology field
What the current treatment options are for alopecia, cutaneous ageing, photodamage, hyperand hypopigmentation disorders, and obesity
Who the market leaders are in the image dermatology field
Which premarket drugs are identified as potential blockbusters
What factors are involved in driving the aesthetic dermatology market
What the sales predictions are for botulinum toxins, retinoids, anorectics, lipase inhibitors, 5-alpha reductase inhibitors, antiandrogenics, hydroquinones, and tretinoin to 2012
Which therapy areas are forecast for high-value growth over the next decade
Which companies are developing novel drugs for aesthetic indications
What are the unmet needs in the antiageing and image dermatology field
Which therapy areas are niche market opportunities
What the future outlook holds for marketed dermatologicals associated with ageing or lifestyle dissatisfaction
What the research and development trends are in image dermatology
Which molecules and compounds are being evaluated with potential indications for antiageing, aesthetics or lifestyle
Which are the top prospects for image dermatology over the next decade and to 2020

Additional Information

COMPANIES MENTIONED IN REPORT

ABBOTT LABORATORIES SERONO
ALIZYME SHIONOGI
ALLERGAN SOLVAY PHARMACEUTICALS
AMGEN STIEFEL LABORATORIES
AMYLIN PHARMACEUTICALS TARGACEPT
ARENA PHARMACEUTICALS VALEANT PHARMACEUTICALS
ASTELLAS PHARMA VERNALIS
BARRIER THERAPEUTICS WYETH
BERTEK PHARMACEUTICALS
BIOACCELERATE
BIOTECON THERAPEUTICS
BIOVITRIUM
BRISTOL-MYERS SQUIBB
CHIRON
CURIS
DAINIPPON SUMITOMO PHARMACEUTICALS
EISAI
ELAN
ENHANCE BIOTECH
EPITAN
FASGEN
GALDERMA
GENAERA
GLADES PHARMACEUTICALS
GLAXOSMITHKLINE
GENADERM
INAMED
INTERCYTEX
IPSEN
ISOLAGEN
KARO BIO
LIGAND
MENTOR
MERCK
MERZ PHARMA
METABOLIC PHARMACEUTICALS
MILLENNIUM
NASTECH
NEUROGEN
OBAGI MEDICAL PRODUCTS
ORTHO-MCNEIL PHARMACEUTICALS
PFIZER
PHERIN PHARMACEUTICALS
PREDIX PHARMA
PHYTOPHARM
ROCHE
SANOFI-AVENTIS
SAPPHIRETHERAPEUTICS

List of Tables
List of Figures
Executive Summary: Objectives of the Report Briefing; Research Methodology
Chapter 1 Introduction to Antiageing and Image Dermatology: Ageing and life Enhancement; Alopecia; Dermal Pigmentation; Lipodermal Disorders
Chapter 2 Image Dermatology Drug Markets: Alopecia; Cutaneous Ageing; Dermal Pigmentation Conditions; Lipodermal Conditions
Chapter 3 Drugs in Research and Development: Introduction; Alopecia; Dermal Ageing; Pigmentation Conditions; Lipodermal Conditions; Obesity
Chapter 4 Market Analysis, Therapy Forecasting, and Prospect Mining: Introduction: Data Analysis, Therapy Forecasting, and Prospect Mining; Comparative Analysis: Product Sales; Prospect Mining
Chapter 5 Report Synopsis: Dermatology; Bibliography and Reference Sources
List of Tables: Table 1.1 Types of Alopecia; Table 1.2 Features of Intrinsic Chronological Cutaneous Ageing and Photoageing; Table 1.3 Factors Associated with Dermal Ageing; Table 1.4 Types of Solar Radiation; Table 1.5 Common Hyperpigmentation Disorders; Table 1.6 Types of Hypopigmentation Disorders; Table 1.7 Calculating Body Mass Index; Table 1.8 Aetiological Factors Associated with Obesity; Table 1.9 Health Risks and Comorbidities Associated with Obesity; Table 1.10 Psychological, Behavioural, and Socioenvironmental Factors Associated with Obesity; Table 2.1 Estimated Global Sales & Forecasts of Drugs for Alopecia (US$m), 2004-; Table 2.2 Estimated Global Sales & Forecasts of Dermal Antiageing Products, 2004-; Table 2.3 Topical Antiageing/Photodamage Products, 2005; Table 2.4 Estimated Global Sales & Forecasts of Products for Pigmentation Conditions, 2004-2012; Table 2.5 Pharmaceutical Products to Treat Common Dermal Pigmentation, 2005; Table 2.6 Estimated Global Sales & Forecasts of Antiobesity Drugs, 2004-2012; Table 3.1 Drugs in Development for Alopecia, 2005; Table 3.2 Drugs in Development for Dermal Ageing, 2005; Table 3.3 Drugs in Development for Pigmentation Disorders, 2005; Table 3.4 Drugs in Development for Gynoid Lipodystrophy (Cellulite), 2005; Table 3.5 Drugs in Development for Obesity, 2005; Table 3.6 Drugs in Development for Appetite Stimulation and Lipodystrophy, 2005; Table 4.1 Global Drug Market for Dermatological Conditions Associated with Ageing and Lifestyle Dysfunction (US$m), 2004-2012
List of Figures: Figure 1.1 Factors Involved in Normal Body Weight Regulation; Figure 2.1 Projected Growth Rates for Alopecia Drugs, 2005-2012; Figure 2.2 Estimated Global Sales of Alopecia Drugs, 2004-2012; Figure 2.3 Projected Growth Rates for Cutaneous Antiageing Products, 2005 & 2012; Figure 2.4 Estimated Global Sales of Dermal Antiageing Products, 2004-2012; Figure 2.5 Projected Growth Rates of Products for Pigmentation Conditions, 2005 & 2012; Figure 2.6 Estimated Global Sales of Products for Pigmentation Conditions, 2004-2012; Figure 2.7 Projected Growth Rates of Current Antiobesity Drugs, 2005-2012; Figure 2.8 Estimated Global Sales of Antiobesity Drugs, 2004-2012; Figure 2.9 Main Drivers of Growth in the Antiobesity Pharmacotherapeutic Market; Figure 4.1 Dermatological Therapy Area Forecasts, 2005 & 2012 (US$m); Figure 4.2 Market Share of Dermatological Therapy Areas, 2005 & 2012; Figure 4.3 Comparative Analysis of Leading Dermatology Products, 2004-2012 (US$m); Figure 4.4 Key Alopecia Drug Prospects in the Antiageing and Life Enhancement Development Pipeline, 2005; Figure 4.5 Key Dermal Ageing Prospects in the Antiageing and Life Enhancement Development Pipeline, 2005; Figure 4.6 Key Dermal Pigmentation Drug Prospects in the Antiageing and Life Enhancement Development Pipeline, 2005; Figure 4.7 Key Lipodermal Drug Prospects in the Antiageing and Life Enhancement Development Pipeline, 2005

More Global Dermatology Reports

Alopecia Global Clinical Trials Review, H1, 2012 by GlobalData
Alopecia Global Clinical Trials Review, H1, 2012 Summary GlobalData's clinical trial report, “Alopecia Global Clinical Trials Review, H1, 2012 provides data on the Alopecia clinical trial scenario. ...

Botulinum Toxin by Global Industry Analysts
This report analyzes the worldwide markets for Botulinum Toxin in US$ Million by the following Product Segments: Cosmetic Applications, and Therapeutic Applications. The report ...

World Market for Prescription Dermatological Drugs, 8th Edition (Antiacne, Antiaging, Dermatitis, Hair Loss, Psoriasis, Skin Cancer, Melasma and Seborrhea Treatments) by Kalorama Information
This Kalorama Information report, The Worldwide Market for Prescription Dermatological Drugs represents the eighth time that Kalorama has detailed the various categories of prescription dermatological ...

Dermatological Drugs: World Market Prospects 2012-2022 by Visiongain
Where are dermatological treatments heading? Visiongain's report shows you potential revenues to 2022, with data, forecasts and discussions. This study assesses drugs to treat ...

Dermatological Drugs: World Market Prospects 2012-2022 by Visiongain
Where are dermatological treatments heading? Visiongain's report shows you potential revenues to 2022, with data, forecasts and discussions. This study assesses drugs to treat ...

See all reports like this >>

The Global Image Dermatology Drug Market, 2005-2012: High-Growth Opportunities in Aesthetic Medicine

Share this report

Other tasks

Research Assistance

Related Markets

Dermatology Reports

Free Alert Me service